Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.493
Filtrar
Mais filtros

Intervalo de ano de publicação
1.
Arch Toxicol ; 98(10): 3209-3214, 2024 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-39017690

RESUMO

Are all food ingredients, dietary supplement ingredients and even foods, required to meet the same safety standards? Are they all equally safe? If so, then why do the various categories have different expressions describing their safety, such as "reasonable certainty of no harm" for food ingredients and "reasonable expectation of no harm" for dietary supplement ingredients? The basis for these different expressions is that they are not standards of safety, but standards of proof of safety. Just as in criminal vs. civil courts, the threshold for proving guilt or fault is different, so too are there differences between various categories of consumer products regulated by the US Food and Drug Administration. This manuscript describes the threshold requirements for each standard, as well as to the identity of the decision makers on what is safe, their credentials as decision makers and the databases mandated for their use.


Assuntos
Qualidade de Produtos para o Consumidor , United States Food and Drug Administration , Estados Unidos , United States Food and Drug Administration/normas , Humanos , Qualidade de Produtos para o Consumidor/normas , Qualidade de Produtos para o Consumidor/legislação & jurisprudência , Suplementos Nutricionais/normas , Suplementos Nutricionais/efeitos adversos , Inocuidade dos Alimentos , Animais , Medição de Risco
2.
Regul Toxicol Pharmacol ; 149: 105603, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38494042

RESUMO

The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) amends the Food, Drug and Cosmetic Act (FDCA), elevating the standard of proof of safety (better known as a "safety standard") for cosmetics to the standard of a "reasonable certainty … [of] … safe."a standard equal to that of food ingredients. The standards of the proof of safety differ for various classes of FDA-regulated product categories e.g., cosmetics, dietary supplements, food ingredients and food itself. This manuscript describes the various standards of proof, the essential differences between the standards, key elements required to achieve a particular standard and, compares the standards to more familiar legal terms such as "a preponderance of the evidence" or "beyond reasonable doubt." The standards of proof for these product categories are also ranked according to increasing threshold for achievement of "safe" status. Lastly, this manuscript suggests how the requirements for the high standard of a "reasonable certainty of safe" (or "reasonable certainty of no harm") might be met.


Assuntos
Qualidade de Produtos para o Consumidor , Cosméticos , United States Food and Drug Administration , Animais , Humanos , Qualidade de Produtos para o Consumidor/normas , Qualidade de Produtos para o Consumidor/legislação & jurisprudência , Cosméticos/normas , Medição de Risco , Estados Unidos , United States Food and Drug Administration/normas
3.
Contact Dermatitis ; 90(6): 594-606, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38471795

RESUMO

INTRODUCTION: Medical devices (MDs) have a long history of use, and come with regulatory frameworks to ensure user safety. Although topically applied MDs in the form of gels and creams might be used on damaged skin, their composition is often similar to that of cosmetic products applicable to intact skin, especially in terms of preservatives and fragrances. However, unlike cosmetics, these products are not subject to compound-specific restrictions when used in MDs. OBJECTIVE: This study aimed to identify and quantify preservatives and fragrances in topically applied MDs and assess their safety towards the Cosmetic Regulation (EC) 1223/2009. METHOD: Sixty-nine MDs available on the EU market were subjected to previously validated liquid chromatography tandem mass spectrometry (LC-MS/MS) and gas chromatography-mass spectrometry (GC-MS) methods to identify and quantify occurring preservatives and fragrances. RESULTS: Findings revealed that 32% of the examined MDs did not provide comprehensive ingredient lists, leaving users uninformed about potential risks associated with product use. Furthermore, 30% of these MDs would not meet safety standards for cosmetic products and, most significantly, 13% of the analysed samples contained ingredients that are prohibited in leave-on cosmetics. CONCLUSION: Results highlight the pressing demand for more stringent requirements regarding the labelling and composition of MDs to enhance patient safety. Improved regulation and transparency can mitigate potential risks associated with the use of topically applied MDs.


Assuntos
Cromatografia Gasosa-Espectrometria de Massas , Conservantes Farmacêuticos , Conservantes Farmacêuticos/análise , Conservantes Farmacêuticos/efeitos adversos , Humanos , Perfumes/efeitos adversos , Perfumes/análise , Cosméticos/análise , Cosméticos/efeitos adversos , Equipamentos e Provisões/efeitos adversos , União Europeia , Espectrometria de Massas em Tandem , Cromatografia Líquida , Qualidade de Produtos para o Consumidor/legislação & jurisprudência , Administração Tópica
4.
Eye Contact Lens ; 50(6): 243-248, 2024 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-38477759

RESUMO

OBJECTIVES: To determine the compliance of online vendors to the UK Opticians Act 1989 Section 27 requirements and safety regulations for cosmetic contact lens (CCL) sales and the quality of online CCL health information. METHODS: The top 50 websites selling CCLs on each three search engines, namely Google, Yahoo, and Bing, were selected. Duplicates were removed, and the remaining websites were systematically analyzed in February 2023. UK legal authorization for CCL sales was assessed using the Opticians Act Section 27 and safety regulations determined by the presence of Conformité Européene (CE) marking. The quality and reliability of online information was graded using the DISCERN (16-80) and JAMA (0-4) scores by two independent reviewers. RESULTS: Forty-seven eligible websites were analyzed. Only six (12.7%) met the UK legal authorization for CCL sales. Forty-nine different brands of CCLs were sold on these websites, of which 13 (26.5%) had no CE marking. The mean DISCERN and JAMA benchmark scores were 26 ± 12.2 and 1.3 ± 0.6, respectively (intraclass correlation scores: 0.99 for both). CONCLUSIONS: A significant number of websites provide consumers with easy, unsafe, and unregulated access to CCLs. Most online stores do not meet the requirements set out in the Opticians Act for CCL sales in the United Kingdom. A significant number of CCLs lack CE marking, while the average quality of information on websites selling CCLs is poor. Together, these pose a risk to consumers purchasing CCLs from unregulated websites, and therefore, further stringent regulations on the online sales of these products are needed.


Assuntos
Informação de Saúde ao Consumidor , Internet , Humanos , Reino Unido , Informação de Saúde ao Consumidor/normas , Cosméticos/normas , Lentes de Contato , Qualidade de Produtos para o Consumidor/legislação & jurisprudência , Qualidade de Produtos para o Consumidor/normas
5.
Artigo em Russo | MEDLINE | ID: mdl-39003540

RESUMO

Various dietary supplements are used as prevention, and in some cases treatment, of a large number of pathological processes in the human body. The purchase of such dietary supplements on various online platforms, including marketplaces, as evidenced by the results of monitoring the Russian online market for 2021-2022, turned out to be the riskiest for human life and health: the components actually contained do not correspond to the declared ones, the presence of Dietary supplement of prohibited substances, lack of a state registration certificate, the presence of which confirms the safety of such dietary supplement for use. The listed violations in the conditions of complete lack of control during the sale of dietary supplements on marketplaces confirm the danger to health, and in some cases, to human life. Uncontrolled use of such products can lead to serious side effects and complications: allergic reactions, kidney failure, liver failure, complications from the gastrointestinal tract, nervous system and genitourinary tract. In this regard, issues related to ensuring the safety of human health and life in the event of their purchasing dietary supplements on marketplaces are relevant. The analysis carried out in the study confirmed the existence of a problem of unreliable declaration of imported dietary supplements on marketplaces by participants in foreign economic activity. In this regard, this article examines the requirements of technical regulations that must be observed when importing dietary supplements into the territory of the EAEU, studies in detail the issue of the possibility of selling imported dietary supplements on marketplaces, and formulates appropriate conclusions and recommendations for eliminating identified problems, which will eliminate possible sales of low-quality products on the marketplace. and prohibited products and identify sellers selling dietary supplements with violations.


Assuntos
Suplementos Nutricionais , Humanos , Federação Russa , Comércio/legislação & jurisprudência , Qualidade de Produtos para o Consumidor/legislação & jurisprudência
6.
J Appl Toxicol ; 40(11): 1511-1525, 2020 11.
Artigo em Inglês | MEDLINE | ID: mdl-32608137

RESUMO

The European Union (EU) continuously takes ensuring the safe use of manufactured nanomaterials (MNMs) in consumer products into consideration. The application of a common approach for testing MNMs, including the use of optimized protocols and methods' selection, becomes increasingly important to obtain reliable and comparable results supporting the regulatory framework. In the present study, we tested four representative MNMs, two titanium dioxides (NM100 and NM101) and two silicon dioxides (NM200 and NM203), using the EU FP7-NANoREG approach, starting from suspension and dispersion preparations, through to their characterization and final evaluation of biological effects. MNM dispersions were prepared following a refined NANOGENOTOX protocol and characterized by dynamic light scattering (DLS) in water/bovine serum albumin and in media used for in vitro testing. Potential genotoxic effects were evaluated on human bronchial BEAS-2B cells using micronucleus and Comet assays, and pro-inflammatory effects by cytokines release. Murine macrophages RAW 264.7 were used to detect potential innate immune responses using two functional endpoints (pro-inflammatory cytokines and nitric oxide [NO] production). The interaction of MNMs with RAW 264.7 cells was studied by electron microscopy. No chromosomal damage and slight DNA damage and an oxidative effect, depending on MNMs, were observed in bronchial cells. In murine macrophages, the four MNMs directly induced tumor necrosis factor α or interleukin 6 secretion, although at very low levels; lipopolysaccharide-induced NO production was significantly decreased by the titania and one silica MNM. The application of this approach for the evaluation of MNM biological effects could be useful for both regulators and industries.


Assuntos
Política de Saúde/legislação & jurisprudência , Imunidade Inata/efeitos dos fármacos , Nanopartículas Metálicas/toxicidade , Nanotecnologia/legislação & jurisprudência , Dióxido de Silício/toxicidade , Titânio/toxicidade , Testes de Toxicidade , Animais , Brônquios/efeitos dos fármacos , Brônquios/imunologia , Brônquios/metabolismo , Brônquios/patologia , Sobrevivência Celular/efeitos dos fármacos , Ensaio Cometa , Qualidade de Produtos para o Consumidor/legislação & jurisprudência , Citocinas/metabolismo , Células Epiteliais/efeitos dos fármacos , Células Epiteliais/imunologia , Células Epiteliais/metabolismo , Células Epiteliais/patologia , Europa (Continente) , União Europeia , Regulamentação Governamental , Humanos , Mediadores da Inflamação/metabolismo , Macrófagos/efeitos dos fármacos , Macrófagos/imunologia , Macrófagos/metabolismo , Macrófagos/patologia , Camundongos , Micronúcleos com Defeito Cromossômico/induzido quimicamente , Testes para Micronúcleos , Formulação de Políticas , Células RAW 264.7 , Medição de Risco
7.
Bioethics ; 34(3): 235-241, 2020 03.
Artigo em Inglês | MEDLINE | ID: mdl-31633831

RESUMO

This paper argues that the Food and Drug Administration's (FDA) policy for health and wellness apps is ethically problematic. Currently, the FDA does not regulate health and wellness apps that are not intended for medical use. As a result of this hands-off policy, preventing harm to consumers is left primarily to developers and app marketplaces. We argue that the FDA's duties to prevent harm and maintain accountability to the American public require that they play a much stronger role. We also discuss concerns about efficiency and fostering innovation, and argue that while they should help shape FDA regulation of health and wellness apps, they do not justify complete absence of FDA involvement.


Assuntos
Qualidade de Produtos para o Consumidor/legislação & jurisprudência , Estilo de Vida Saudável , Aplicativos Móveis/legislação & jurisprudência , Regulamentação Governamental , Humanos , Política Organizacional , Estados Unidos , United States Federal Trade Commission/legislação & jurisprudência , United States Food and Drug Administration/legislação & jurisprudência
8.
Contact Dermatitis ; 82(4): 247-250, 2020 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-31811647

RESUMO

Highlights After the introduction of the EU regulatory interventions, nickel sensitization decreased significantly in the group of females aged ≤25 years. Women born between 1966 and 1975 presented the higheest prevalence of sensitization to nickel, then prevalence of sensitization gradually decreased with a minimum in more recent years. Nickel sensitization is higher in Italian patients compared to people living in other EU coutries. Additional interventions are needed to address nickel sensitization.


Assuntos
Qualidade de Produtos para o Consumidor/legislação & jurisprudência , Dermatite Alérgica de Contato/epidemiologia , Níquel/efeitos adversos , Adulto , Idoso , União Europeia , Feminino , Humanos , Itália/epidemiologia , Masculino , Pessoa de Meia-Idade , Testes do Emplastro , Prevalência , Adulto Jovem
9.
Contact Dermatitis ; 82(4): 218-226, 2020 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-31626332

RESUMO

BACKGROUND: In 2001, the EU nickel directive was introduced to prevent contact allergy to nickel. Contact allergy to palladium and/or cobalt is often seen together with contact allergy to nickel. OBJECTIVES: To compare the contact allergy prevalence of nickel, palladium, and cobalt allergy before and after the introduction of the EU nickel directive in consecutive patients with dermatitis. METHODS: A retrospective analysis of patch test results from 1995-2016 was performed (n = 18 264). Chi-square tests were used to examine trends for nickel, palladium, and cobalt across test years. Logistic regression was used for associations. RESULTS: The prevalence of nickel allergy decreased significantly in the youngest age group (6-30 years) for both female and male patients from 1995-1999 to 2012-2016: females: 33.4% to 19.1% (P < .001); males: 5.9% to 2.1% (P < .05). The concomitant reactions between nickel and palladium and nickel and cobalt among young females, respectively, also decreased significantly. Isolated palladium and cobalt allergy remained stable (1.4% and 2.3%, respectively) during the same time period for both men and women. CONCLUSIONS: The prevalence of nickel has decreased among young females and males suspected of contact allergy in Southern Sweden after the introduction of the EU nickel directive. There has been no change in isolated palladium or cobalt allergy.


Assuntos
Cobalto/efeitos adversos , Qualidade de Produtos para o Consumidor/legislação & jurisprudência , Dermatite Alérgica de Contato/epidemiologia , Níquel/efeitos adversos , Paládio/efeitos adversos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Dermatite Alérgica de Contato/etiologia , Feminino , Humanos , Joias/efeitos adversos , Masculino , Pessoa de Meia-Idade , Testes do Emplastro , Prevalência , Estudos Retrospectivos , Suécia/epidemiologia , Adulto Jovem
10.
Toxicol Mech Methods ; 30(8): 555-561, 2020 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-32746758

RESUMO

Menthol, which is a natural cyclic monoterpene alcohol with a minty smell, is one of the main constituents of essential oils that naturally occur in some aromatic plants, such as Mentha × piperita L. This natural compound shows many biological properties, such as anesthetic, analgesic, antibacterial and antifungal, immunomodulating, and skin penetration-enhancing. It is added to a variety of goods, such as food, oral-care products, OTC products, cosmetics, and tobacco products. Menthol is not just a simple flavoring agent, especially when it comes to tobacco products. Its ability to 'mask' the negative effects of nicotine and its additional positive sensory effects makes it the most common additive in such products. For the customers, mentholated tobacco products may be mistakenly perceived as less harmful for health, which may increase their consumption. However, as the evidence shows, menthol cigarettes are no safer than conventional cigarettes and may lead to more frequent disease exacerbation during prolonged exposure to smoke from such products. In addition, because of its complex interactions with nicotine, menthol may affect smoking behavior and may increase addiction to nicotine. For those reasons, the European Union banned flavored cigarettes (whose sale size reached more than 3% of the total tobacco product market) by implementing the Tobacco Products Directive (2014/40/EU) on 20th May 2020. While the menthol ban was based on health concerns, the ultimate effect on consumers, regarding potential quitting, is yet to be determined.


Assuntos
Qualidade de Produtos para o Consumidor , Aromatizantes/efeitos adversos , Mentol/efeitos adversos , Produtos do Tabaco/efeitos adversos , Fumar Tabaco/efeitos adversos , Tabagismo , Animais , Comércio , Qualidade de Produtos para o Consumidor/legislação & jurisprudência , Europa (Continente) , União Europeia , Humanos , Mentol/análogos & derivados , Medição de Risco , Abandono do Hábito de Fumar , Produtos do Tabaco/legislação & jurisprudência , Fumar Tabaco/legislação & jurisprudência
11.
Transgenic Res ; 28(2): 267-286, 2019 04.
Artigo em Inglês | MEDLINE | ID: mdl-30838488

RESUMO

The European Court of Justice's recent ruling that the new techniques for crop development are to be considered as genetically modified organisms under the European Union's regulations exacerbates the need for a critical evaluation of those regulations. The paper analyzes the regulation from the perspective of moral and political philosophy. It considers whether influential arguments for restrictions of genetically modified organisms provide cogent justifications for the policies that are in place, in particular a pre-release authorization requirement, mandatory labelling, and de facto bans (in the form of withholding or opting out of authorizations). It is argued that arguments pertaining to risk can justify some form of pre-release authorization scheme, although not necessarily the current one, but that neither de facto bans nor mandatory labelling can be justified by reference to common arguments concerning naturalness, agricultural policy (in particular the promotion of organic farming), socio-economic effects, or consumers' right to choose.


Assuntos
Qualidade de Produtos para o Consumidor/legislação & jurisprudência , Produtos Agrícolas/genética , Alimentos Geneticamente Modificados , Engenharia Genética/legislação & jurisprudência , Plantas Geneticamente Modificadas , Medição de Risco/legislação & jurisprudência , Gestão da Segurança/legislação & jurisprudência , União Europeia , Engenharia Genética/métodos , Engenharia Genética/normas , Humanos , Legislação sobre Alimentos , Medição de Risco/métodos , Medição de Risco/normas , Gestão da Segurança/métodos , Gestão da Segurança/normas
12.
Inhal Toxicol ; 31(1): 12-24, 2019 01.
Artigo em Inglês | MEDLINE | ID: mdl-30995882

RESUMO

Seventy-one percent of US households purchase air care products. Air care products span a diverse range of forms, including scented aerosol sprays, pump sprays, diffusers, gels, candles, and plug-ins. These products are used to eliminate indoor malodors and to provide pleasant scent experiences. The use of air care products can lead to significant benefits as studies have shown that indoor malodor can cause adverse effects, negatively impacting quality of life, hygiene, and the monetary value of homes and cars, while disproportionately affecting lower income populations. Additionally, studies have also shown that scent can have positive benefits related to mood, stress reduction, and memory enhancement among others. Despite the positive benefits associated with air care products, negative consumer perceptions regarding the safety of air care products can be a barrier to their use. During the inaugural Air Care Summit, held on 18 May 2018 in the Washington, DC, metropolitan area, multidisciplinary experts including industry stakeholders, academics, and scientific and medical experts were invited to share and assess the existing data related to air care products, focusing on ingredient and product safety and the benefits of malodor removal and scent. At the Summit's completion, a panel of independent experts representing the fields of pulmonary medicine, medical and clinical toxicology, pediatric toxicology, basic science toxicology, occupational dermatology and experimental psychology convened to review the data presented, identify potential knowledge gaps, and suggest future research directions to further assess the safety and benefits of air care products.


Assuntos
Qualidade de Produtos para o Consumidor , Odorantes , Poluição do Ar em Ambientes Fechados , Asma , Qualidade de Produtos para o Consumidor/legislação & jurisprudência , Regulamentação Governamental , Humanos , Exposição por Inalação , Medição de Risco , Segurança
13.
Regul Toxicol Pharmacol ; 103: 106-112, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-30659873

RESUMO

Personal lubricants and lubricants used in condoms contain a number of ingredients which are also present in cosmetic products. These have to comply to the medical device regulation (745/2017) which should provide the same level of consumer protection, if not more, as foreseen in the legal framework of cosmetics (1223/2009). In the current study we developed an analytical method capable of identifying and quantifying 15 ingredients, commonly found in lubricants and cosmetics. Based upon their most important toxicological endpoint, the substances involved were grouped in three toxicological classes provoking either irritation, contact allergic dermatitis or systemic toxicity. The method was applied on 30 condoms and 54 personal lubricants present on the EU market. Their safety was assessed using the same reasoning as commonly applied for cosmetic ingredients. Higher mucosae susceptibility, the main exposed area for lubricants, was taken into account in this assessment. The results show that the majority of the products studied are safe. Nevertheless, for some products the safety could not be confirmed. The results also highlight the fact that there is no consensus for a number of ingredients, used as well in cosmetics as in medical devices. Alignment between both legislations would improve the safety of these products and further raise the general level of consumer protection.


Assuntos
Preservativos/efeitos adversos , Qualidade de Produtos para o Consumidor/legislação & jurisprudência , Cosméticos/efeitos adversos , União Europeia , Lubrificantes/efeitos adversos , Humanos , Medição de Risco
14.
J Clin Pharm Ther ; 44(1): 134-139, 2019 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-30484882

RESUMO

WHAT IS KNOWN AND OBJECTIVE: Hawaii will ban two major ingredients of sunscreens. This article reviews the reasons and future directions. Hawaii recently enacted legislation that will ban the use of two major ingredients of the majority of commonly used sunscreens. The reason for the ban is the ingredients' putative deleterious impact on marine ecosystems, particularly coral reefs. But sunscreens also save lives by decreasing the risk of UV-induced skin cancers. We review both sides of the issue and potential implications for the healthcare system. COMMENT: Coral reefs consist of organisms in delicate equilibria that are susceptible to small changes in their surroundings. Recent natural and man-made disruptions, direct or indirect, such as changes in ocean temperature and chemistry, ingress of invasive species, pathogens, pollution and deleterious fishing practices, have been blamed for the poor health, or even the outright destruction, of some coral reefs. The most popular sunscreen products contain two ingredients-oxybenzone and octinoxate-that have also been implicated in coral toxicity and will be banned. This creates a healthcare dilemma: Will the protection of coral reefs result in an increase in human skin cancers? WHAT IS NEW AND CONCLUSION: Concentration estimates and mechanism studies support an association-direct or indirect (via promotion of viral infection)-of sunscreens with bleaching of coral reefs. A ban on the two most common sunscreen ingredients goes into effect in Hawaii on January 1, 2021. Proponents suggest that this is a trend, just the first of many such bans worldwide; opponents warn of a dire increase in human skin cancers. As a result, alternative sunscreen compounds are being sought.


Assuntos
Antozoários/efeitos dos fármacos , Benzofenonas/toxicidade , Cinamatos/toxicidade , Protetores Solares/toxicidade , Animais , Benzofenonas/administração & dosagem , Cinamatos/administração & dosagem , Qualidade de Produtos para o Consumidor/legislação & jurisprudência , Recifes de Corais , Havaí , Humanos , Neoplasias Cutâneas/epidemiologia , Neoplasias Cutâneas/prevenção & controle , Protetores Solares/administração & dosagem , Protetores Solares/química
15.
Ophthalmic Plast Reconstr Surg ; 35(3): 294-295, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31793914

RESUMO

PURPOSE: This perspective explores the safety profile of ocular cosmetics and explores the role ophthalmologists can play in mitigating potential ocular harm from unsafe products. METHODS: N/A. RESULTS: Cosmetics and personal care products represent a large industry that is currently unregulated in any meaningful way. Products intended for use around the eyes carry a risk of serious side effects including contact dermatitis and bacterial infection. Currently, legislation has been proposed to change regulation to provide more meaningful oversight of cosmetics. CONCLUSIONS: Ophthalmologists are often the first to recognize patterns in harmful products intended for use around the eye and can help mitigate potential future ocular harm by reporting adverse events to the Food and Drug Administration and by advocating for cosmetic regulation change.


Assuntos
Qualidade de Produtos para o Consumidor/legislação & jurisprudência , Oftalmologia/legislação & jurisprudência , Segurança do Paciente/legislação & jurisprudência , Procedimentos de Cirurgia Plástica/normas , Humanos
17.
Toxicol Mech Methods ; 29(5): 378-387, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-30636497

RESUMO

Nanotoxicology and nanosafety has been a topic of intensive research for about more than 20 years. Nearly 10 000 research papers have been published on the topic, yet there exists a gap in terms of understanding and ways to harmonize nanorisk assessment. In this review, we revisit critically ignored parameters of nanoscale materials (e.g. band gap factor, phase instability and silver leaching problem, defect and instability plasmonic versus inorganic particles) versus their biological counterparts (cell batch-to-batch heterogeneity, biological barrier model design, cellular functional characteristics) which yield variability and nonuniformity in results. We also emphasize system biology approaches to integrate the high throughput screening methods coupled with in vivo and in silico modeling to ensure quality in nanosafety research. We emphasize and highlight the recommendation regarding bridging the mechanistic gaps in fundamental research and predictive biological response in nanotoxicology. The research community has to develop visions to predict the unforeseen problems that do not exist yet in context with nanotoxicity and public health hazards due to the burgeoning use of nanomaterial in consumer's product.


Assuntos
Qualidade de Produtos para o Consumidor , Nanoestruturas/toxicidade , Nanotecnologia/métodos , Testes de Toxicidade/métodos , Animais , Qualidade de Produtos para o Consumidor/legislação & jurisprudência , Qualidade de Produtos para o Consumidor/normas , Regulamentação Governamental , Ensaios de Triagem em Larga Escala , Humanos , Nanoestruturas/química , Nanotecnologia/legislação & jurisprudência , Tamanho da Partícula , Projetos de Pesquisa , Propriedades de Superfície
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA